- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05080985
Paravertebral Block Versus Erector Spinae Plane Block for Analgesia in Modified Radical Mastectomy
Paravertebral Block Versus Erector Spinae Plane Block for Analgesia and Opioid Consumption in Modified Radical Mastectomy; Randomized, Prospective, Double Blind
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
A total of 86 patients were randomized into TPVB (Group P) and ESPB (Group E) by using closed envelopes.
All patients in the operating room has same anesthetic management under standard monitoring modalities. Prior to regional technique, mild sedation was achieved with midazolam (1-2 mg) and fentanyl (50 mcg). Both blocks were performed under ultrasonography guidance from the level of T4 vertebra with a linear probe (5MHz; GE Healthcare, Wauwatosa, Wis, USA) using longitudinally out-of-plane technique by an anesthesiologist. A 22-gauge, 50 mm insulated stimulating needle was used.By using reference points of C7 and T7, spinous processes of thoracic vertebras were marked. 10% povidone iodine was used for skin antisepsis. USG probe was longitudinally placed at the level of T4. Staff anesthesiologist had to visualize of adjacent muscles, transverse process (TP) and pleura.
For ESPB; confirmation of the needle position was achieved with spread of 2 ml saline between the deep fascia of the erector spinae muscle and the TP. After negative aspiration 20 ml 0.375% bupivacaine was injected with appropriate distribution of LA.
For TPVB; the needle was advanced passing over superior costotransverse ligament and target space was confirmed by the downward displacement of pleura after the administration of 2 ml 0.9% NaCl. After negative aspiration, 20 ml 0.375 % bupivacaine was injected with appropriate distribution of local anesthetics.
Vascular puncture, haematoma, neuraxial injury and pneumothorax were defined as block complications and should be noted.
30 minutes after the block achieved, pinprick test was performed on both mid-axillary and midclavicular lines from T1 to T12 (0 there is sensation, 1 decreased sensation, 2 there is no sensation).
Anesthesia induction was unique for all patients with 0.03 mg kg-1 midazolam, 0.5 mcg kg-1 fentanyl, 2 mg kg-1 propofol and 0.6 mg kg-1 rocuronium. Maintenance was achieved with sevoflurane of 1 minimum alveolar concentration in a mixture of 40% O2 and 60% N2O. As a component of multimodal analgesia, paracetamol (1 gr) was applied to all patients before skin incision.
Hemodynamic data were recorded throughout surgery. An increase more than 20% from baseline in mean arterial pressure (MAP) was defined as inadequate analgesia and was treated with bolus fentanyl (50 mcg). Hypotension was described with a decrease more than 20% in MAP and treated with ephedrine bolus. Bradycardia was determined with a heart rate (HR) less than 50 beats min-1 and treated with atropine. At the end of surgery, the patients were extubated in operating room.
Postoperative analgesia was achieved with IV morphine via Patient Controlled Analgesia (PCA) for 24 hours (0.01 mg kg-1 h-1 basal infusion, 1 mg bolus, 20 minutes lock-out time).
Postoperative follow-up included hemodynamic variables as well as pain scores and morphine consumption. Adequate analgesia at rest (static) and at moving of the arm interpreted as 45-90 degree abduction (dynamic) was investigated with Numeric Rating Scale (NRS) at 30th minute and 1st, 4th, 6th, 12th, 24th hours postoperatively. When NRS was 4 and higher, tramadol should be administered as rescue analgesic. In case of insufficient pain control at 30th minute, dermatomal analgesia should be assessed for both mid-axillary and midclavicular lines from T1 to T8 by pinprick test (0 there is sensation, 1 decreased sensation, 2 there is no sensation). Morphine consumption was evaluated at same study times.
Complications were determined as sedation assessed by Ramsey scale, postoperative nausea- vomiting (PONV) assessed with the four-point categorical scale (0=no PONV, 1=mild nausea, 2=severe nausea or vomiting once, and 3=vomiting more than once). Severe vomiting should be treated in a multimodal way and excluded from the study (category 2,3).
Staff anesthesiologist responsible for operative course did not contribute in analgesia assessment, nor in other postoperative follow-up. Other investigators who were blinded to operative management, collected postoperative data.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Istanbul, Pavo, 34093
- Istanbul University, Istanbul Faculty of Medicine
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- unilateral MRM
- ages 18-75 years
- American Society of Anesthesiologists (ASA) classification I-III
Exclusion Criteria:
- presence of contraindications for using regional anesthesia (not having patient approval, presence of bleeding-clotting disorders, infection at the injection site, local anesthetic allergy)
- chronic analgesic use
- diabetes mellitus
- body mass index of (BMI) > 35 kg/m2.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Group P : TPVB
Thoracic paravertebral block
|
20 ml 0.375 % bupivacaine was injected between superior costotransverse ligament and pleura.
20 ml 0.375 % bupivacaine was injected
|
Experimental: Group E : ESPB
Erector spinae plane block
|
20 ml 0.375 % bupivacaine was injected
20 ml 0.375 % bupivacaine was injected between deep fascia of the erector spinae muscle and transverse process.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Morphine consumption
Periodo de tiempo: postoperative 24 hours
|
amount of postoperative 24 hours morphine consumption
|
postoperative 24 hours
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Static and dynamic pain score assessed with Numeric Rating Scale (NRS).
Periodo de tiempo: postoperative 24 hours
|
Pain scores will be noted postoperative at 0, 30 minutes and 1,4,6,12,24 hours.
NRS=0 (minimum value, no pain).
NRS=10 (maximum value, worst pain imaginable).
|
postoperative 24 hours
|
intraoperative heart rate
Periodo de tiempo: during surgery
|
starting from induction to extubation (beat/min)
|
during surgery
|
intraoperative mean arterial pressure
Periodo de tiempo: during surgery
|
starting from induction to extubation (mmHg)
|
during surgery
|
nause and vomit
Periodo de tiempo: postoperative 24 hours
|
Assessed with Postoperative Nause and Vomit (PONV) Scale.
(0=no PONV, 1=mild nausea, 2=severe nausea or vomiting once, and 3=vomiting more than once)
|
postoperative 24 hours
|
number of blocked dermatome
Periodo de tiempo: 30 minutes after block
|
pinprick test in mid-axillar and mid-clavicular line
|
30 minutes after block
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Nükhet Sivrikoz, Attending anesthesiologist
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2018-1608
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre TPVB
-
Ankara City Hospital BilkentReclutamientoDolor agudo | Toracotomía | Analgesia Postoperatoria | Anestesia local | Bloque paravertebral torácicoPavo
-
Kunming Medical UniversityTerminado
-
Koç UniversityTerminadoDolor PostoperatorioPavo
-
Seoul National UniversitySMG-SNU Boramae Medical CenterTerminadoSíndromes de dolor regional complejo | Dolor neuropático | Dolor del miembro fantasma | Neuralgia postherpética | Neuralgia postraumática | Dolor Post Quirúrgico CrónicoCorea, república de
-
Kafrelsheikh UniversityTerminadoAnalgesia | Bloque plano del erector de la columna | Bloque Cuadrado Lumborum | Bloque paravertebralEgipto
-
Istanbul UniversityTerminadoObesidad | Dolor Postoperatorio | Rendimiento | Ultrasonido | Bloques paravertebrales torácicos
-
Assiut UniversityAún no reclutandoDolor crónico | Mastectomía; linfedema | Bloque paravertebral | Bloqueo del nervio pectoralEgipto
-
Cui XuleiTerminadoBloqueo Nervioso, Nefrectomía, AnalgesiaPorcelana
-
Shiyou WeiTerminado